Trials / Withdrawn
WithdrawnNCT02828345
Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research trial studies the levels of a type of biomarker, circulating tumor cells (CTCs), in the blood of patients with stage I-IV melanoma. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Studying samples of blood in the laboratory obtained before and after treatment from patients with melanoma may help doctors learn more about changes that occur in CTC levels and whether they may predict how well patients will respond to therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Specimen Collection |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2016-07-11
- Last updated
- 2020-02-05
Source: ClinicalTrials.gov record NCT02828345. Inclusion in this directory is not an endorsement.